Navigation Links
Rifampin: Latent TB treatment saves time money and lives
Date:5/20/2008

ATS 2008, TORONTOA new way to treat patients with latent tuberculosis (TB), who are infected with TB but without symptoms, can effectively treat it in less than half the time and at a lower cost than the current standard treatment, according to researchers who conducted a multi-center, randomized controlled trial. The results will be presented at the American Thoracic Societys 2008 International Conference in Toronto on Tuesday, May 20.

We found that using a therapy of four months of Rifampin instead of the current nine months of Isoniazid costs significantly less for the healthcare system, said lead analyst, Anne Aspler, M.Sc., of the Respiratory Epidemiology & Clinical Research Unit at McGill Universitys Montreal Chest Institute. Overall, Rifampin costs about $484 less per patient treated, which, if we assume that four months of Rifampin has at least equal efficacy to nine months of Isoniazid, represents an added savings to the health system of more than $10,000 per patient prevented from developing TB disease. And because of improvements in compliance, we are actually preventing more cases. This treatment can save money as well as lives.

At present, two billion people are believed to have latent or dormant TB. Of those infected, eight to nine million will develop TB each year, of whom 1.6 million will die. This is one of the most pressing public health crises in our modern world, said Ms. Aspler.

Rifampin is offered in developing countries, where TB presents the greatest burden, at a subsidized cost through the Global Drug Facility of the World Health Organization. In addition to the cost savings, therapy with Rifampin has the advantage of increased compliance.

While Isoniazid therapy is 90 percent effective for those who complete it, in reality, fewer than 50 percent do, Ms. Aspler explained. The high attrition rate can have serious public heath effects, not only for the patients who fail to complete therapy, but also for the individuals they may later infect.

According to previous research and program experience in Maryland and New Jersey, a four-month treatment has been shown to improve compliance by 20 to 25 percent. In addition to better completion rates, a four-month course of Rifampin offers the advantages of fewer adverse reactions (fewer serious side effects such as hepatotoxicity or liver damage), and lower costs.

The next step in research is a major Phase III clinical trial of efficacyideally in HIV-infected and non-infected patients and in low-income settings where tuberculosis is the leading cause of death in people living with HIV, said Ms. Aspler.


'/>"/>

Contact: Keely Savoie
ksavoie@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. New chemical can kill latent tuberculosis bacteria
2. New treatment gives hope for pulmonary fibrosis patients
3. Mission Pharmacal Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
4. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
5. Mapping of prostate cancer genes opens the door to new treatments
6. Many Diabetics Dont Get Necessary Blood Pressure Treatment
7. MR imaging accurately determines prostate cancer treatment failure
8. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
9. Old antibiotic may find new life as a stroke treatment
10. Radiofrequency ablation is effective treatment for dysplasia in Barretts esophagus
11. New Hair Loss Treatment Proves Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Accreditation Commission for ... Care Association of America (HCAOA). This agreement allows HCAOA members to receive special ... as discounts on Accreditation University (AU) educational resources that help prepare HCAOA members ...
(Date:4/28/2017)... , ... April 28, 2017 , ... Horizon Blue Cross ... the company’s credit rating of “A” and its outlook as “stable.” At the same ... reserves, which have fallen in recent years, dip below “capital adequacy” thresholds required for ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... Replace tubes . These lamps offer an instant energy-saving solution for F32T8 fluorescent ... rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize the existing ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... April 28, 2017 , ... Bill Howe started his sewer and drain ... After Tina Howe joined the team, the Bill Howe brand was born and they ... rates, and giving back to the San Diego community in which they worked, lived ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... DUBLIN , April 20, 2017 Research ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ... to their offering. ... market for drug delivery technologies will rise from USD 20 Billion ... Global Drug Delivery Technologies - Innovation Driven by Rapidly ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology: